Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: Analysis of the phase III double-blind, double-dummy, interferon beta-1a-controlled opera I and opera II studies

Authors
Category Primary study
JournalNeurology
Year 2016
This article has no abstract
Epistemonikos ID: 8ce1c7dde94fe8afc5ddd2d7f4b642ee803166db
First added on: Feb 07, 2025